Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 2/3 2Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Urinary Bladder Neoplasms 1Breast Neoplasms 1

Interventions

Oxaliplatin 11Docetaxel 8Fluorouracil 6Capecitabine 6Trastuzumab 5Leucovorin 5Drug Therapy 5apatinib 4S 1 (combination) 4Tegafur 3Paclitaxel 3Nivolumab 3Irinotecan 3Cisplatin 3sintilimab 2disitamab vedotin 2Surgical Procedures, Operative 2Standard of Care 2Ramucirumab 2Hyperthermic Intraperitoneal Chemotherapy 2Epirubicin 2vinflunine 1toripalimab 1titanium silicide 1tislelizumab 1taxane 1polysaccharide-K 1pertuzumab 1margetuximab 1gimeracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Stomach Neoplasms × disitamab vedotin × Clear all
NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

RemeGen Co., Ltd.

Phase 2/3 Active not recruiting
201 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06221748 2024-04-03

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

RemeGen Co., Ltd.

Phase 2/3 Recruiting
90 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡